Identification of novel chemical scaffolds that inhibit the growth of Mycobacterium tuberculosis in macrophages
Abstract
Mycobacterium tuberculosis is an important global pathogen for which new drugs are urgently required. The ability of the organism to survive and multiply within macrophages may contribute to the lengthy treatment regimen with multiple drugs that are required to cure the infection. We screened the MyriaScreen II diversity library of 10,000 compounds to identify novel inhibitors of M. tuberculosis growth within macrophage-like cells using high content analysis. Hits were selected which inhibited the intramacrophage growth of M. tuberculosis without significant cytotoxicity to infected macrophages. We selected and prioritized compound series based on their biological and physicochemical properties and the novelty of the chemotypes. We identified five chemical classes of interest and conducted limited catalog structure-activity relationship studies to determine their tractability. We tested activity against intracellular and extracellular M. tuberculosis, as well as cytoxicity against murine RAW264.7 and human HepG2 cells. Benzene amide ethers, thiophene carboxamides and thienopyridines were only active against intracellular bacteria, whereas the phenylthiourea series was also active against extracellular bacteria. One member of a phenyl pyrazole series was moderately active against extracellular bacteria. We identified the benzene amide ethers as an interesting series for further work. These new compound classes serve as starting points for the development of novel drugs to target intracellular M. tuberculosis.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis
J. Ollinger, A. Kumar, … T. Parish·bioRxiv·Sep 27, 2018
- Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis
Claire Naylor, Gareth A. Prosser, … Laura A. T. Cleghorn·ACS Infectious DiseasesPeer-reviewed·May 14, 2026
- Discovery, Synthesis, and Optimization of 1,2,4-Triazolyl Pyridines Targeting Mycobacterium tuberculosis
S. Roy, T. Berida, … C. L. Stallings·bioRxiv·Nov 14, 2022
- Discovery of benzophenanthridine derivatives with potent activity against multidrug resistant Mycobacterium tuberculosis
Z. Sun, Y. C. Liang, … J. Sun·bioRxiv·Nov 7, 2022
- Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly.
A. B. Lanne, Y. Cui, … L. J. Alderwick·bioRxiv·Sep 3, 2020
- Rapid Screening and Validation of Intracellularly Active Antimycobacterial Compounds with Efficacy in Cellular and Murine Tuberculosis Models
Mahima Madan, Kanika Bisht, … Vivek Rao·bioRxiv·Sep 23, 2025